Fate Therapeutics, Inc. (FATE) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

58NeutralDD: Jun 10, 2026Analyst: 60

paidPrice at analysis date

USD 1.94 (10/06/2026)

domainMkt cap

$222M

pie_chartShares

115.35M

candlestick_chart52W

$0.91-$2.88

trending_downShort interest

9.92%

INFONasdaq Global Select MarketHealth Care181 employeesFounded 2007

Verdict: Moderately Attractive —

Post-Janssen-pivot clinical biotech with $174.8M cash (~79% of market cap), runway into 2028, and binary catalyst H2 2026 (RECLAIM-LN Phase 2 registrational in lupus nephritis). FT819 Phase 1 SLE data clean on safety (n=21, no Grade >2 CRS). Cash floor $1.52/sh limits downside vs current $1.94; consensus $5.27 implies wide reward gap if execution holds. Expected dilution and crowded autoimmune CAR T space cap the base case.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-06-10

Fate Therapeutics (FATE)

Clinical-Stage Biotech · iPSC CAR T/NK · NASDAQ · San Diego, CA

"Cash floor + binary RECLAIM-LN catalyst; consensus stretch vs base FV underscores execution risk."

Cash $174.8M (~79% mkt cap) RECLAIM-LN initiation H2 2026 FDA CDRP designation Runway into 2028 (~24 months) 2023 class action pending Dilution +8.8% YoY

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — rNPV per program + Net cash floor − Expected dilution haircut

Fair value base case

USD 2.80

Range: USD 1.90-USD 4.40

Price at analysis date: USD 1.94 (10/06/2026)

Base upside/downside: +44%

Methodology: rNPV bottom-up per program + net cash floor + dilution haircut. PoA assumptions Phase 2 start: 25% for FT819 LN, 20% for FT819 SLE — consistent with industry biotech PoA database for autoimmune cell therapy at this stage. NPV discount at 12% over 6 years for LN, 8 years for broader SLE. Cross-check via peer EV/Cash multiple (0.85x peer median ex-CRBU outlier) within ±1% of rNPV base. Sensitivity: ±5% on FT819 LN PoA = ±$0.20/sh; eliminating dilution haircut adds $0.85/sh. ⚠️ Not investment advice.

Component	Assumption	USD/share
Net cash floor	$174.8M cash − ~$0 debt = $174.8M / 115.35M shares	+1.52
FT819 rNPV — Lupus nephritis (RECLAIM-LN)	$1.5B peak sales × 25% PoA (Phase 2 starting) × 60% net margin × 0.50 NPV factor (6-yr discount @ 12%) → $112M / 115.35M shares	+0.97
FT819 rNPV — Broader SLE indication	$0.8B peak sales × 20% PoA × 60% × 0.40 NPV factor → $38M / 115.35M shares	+0.33
FT522 (CAR NK) + FT825 + FT836 + FT839 rNPV	4 early programs × $20M risk-adjusted NPV each → $80M / 115.35M shares	+0.69
iPSC platform M&A optionality	$50M platform value × 30% probability of strategic transaction → $15M / 115.35M shares	+0.13
Expected dilution haircut	$100M raise at ~$2.50 = +40M shares (35% dilution) × 25% PV adjustment	−0.85
FV base case	Sum of components above	≈ $2.80

Bull

$4.50–6.00

Probability: 25%

RECLAIM-LN initiates on schedule, FT819 SLE/LN data continues to show high CRR signal at next data cuts, FT839 IND clears, partner interest re-emerges. Re-rating toward consensus average $5.27 / high $8.00. Possible cash raise at $4+.

Base

$2.40–3.40

Probability: 50%

RECLAIM-LN initiates H2 2026, Phase 1 SLE updates support narrative, peer re-rating closes part of EV/Cash discount. Equity raise needed by H2 2027 at ~$2.50, dilution priced in. Multiple expansion modest.

Bear

$1.10–1.70

Probability: 25%

RECLAIM-LN initiation slips to 2027, FT819 SLE efficacy signal weakens at next data cut, autoimmune CAR T competitive pressure intensifies (Cabaletta, Allogene). Forced dilutive raise at $1.20-1.50. 52W low $0.91 = absolute floor.

Methodology: Methodology: rNPV bottom-up per program + net cash floor + dilution haircut. PoA assumptions Phase 2 start: 25% for FT819 LN, 20% for FT819 SLE — consistent with industry biotech PoA database for autoimmune cell therapy at this stage. NPV discount at 12% over 6 years for LN, 8 years for broader SLE. Cross-check via peer EV/Cash multiple (0.85x peer median ex-CRBU outlier) within ±1% of rNPV base. Sensitivity: ±5% on FT819 LN PoA = ±$0.20/sh; eliminating dilution haircut adds $0.85/sh. ⚠️ Not investment advice. Not investment advice.

check_circle

✅ Recent positive datapoint — FDA CDRP Program selection for FT819 (Q1 2026) + ECR data (June 4, 2026)

FDA selected FT819 into the CMC Development and Readiness Pilot program, enabling enhanced FDA communication to accelerate clinical timelines. June 4 2026 ECR (European Congress of Rheumatology) presentation reinforced clean safety profile: 21 SLE patients treated in Phase 1, all Regimen A tolerated without DLT, no Grade >2 CRS. RECLAIM-LN (Phase 2 potentially registrational) on schedule to initiate H2 2026 — the key catalyst for the equity story.

⚠️ Methodology note: Pre-commercial clinical-stage biotech → rNPV (probability-weighted NPV per program) + net cash floor + expected dilution haircut, NOT EV/EBITDA or EV/Revenue (revenue is $5M collaboration only). Multiple binary catalyst events shape scenarios.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

9.92%

11.44M shares shorted on 115.35M outstanding. Moderate level (5-15% band). Bearish positioning reflects skepticism on FT819 PoA + dilution risk.

🔴 Share dilution (1Y)

+8.77%

From ~106M to 115.35M shares. Equity-comp + likely small ATM utilization. With runway only to 2028, additional dilution highly probable next 12 months.

🔴 Buyback

No buyback program. $174.8M cash preserved for trial execution. Capital allocation priority: RECLAIM-LN + Phase 1 SLE expansion + multiple programs progression.

Short Interest — context

FATE — 9.92%

9.92%

Short interest 9.92% is moderate for a clinical-stage biotech, reflecting (i) post-Janssen 2023 trauma still in market memory, (ii) heavy competition in autoimmune CAR T (Cabaletta, Allogene, Caribou, Kyverna), and (iii) certainty of equity raise within 18 months. Limited squeeze potential on positive Phase 2 catalyst, but data-driven re-rating dominates.

Insider transactions (last 12 months): Form 4 filings show routine officer-level RSU vesting with tax-withholding sales (no material open-market sales >$500K threshold identified). No insider buying. Note: a 2023 securities class action (Wolchko CEO, Dulac CFO, Valamehr CRDO named) related to Janssen termination remains in litigation; no resolution disclosed as of June 2026. Class period: April 2, 2020 – January 5, 2023. No new lawsuits, SEC investigation, or short-seller report identified in trailing 12 months.

$Financial analysis — FY 2024 / FY 2025 / Q1 2026

Cash + investments

$174.8M

Runway into 2028 (~24 mos)

Net loss Q1 26 (TTM ~$130M)

−$31.2M

-20% YoY OpEx after restructuring

Cash / market cap

~79%

$1.52/sh cash floor

Debt

~Zero

D/E 0.54 (mostly leases)

Item	FY2023	FY2024	FY2025	Q1 2026	Guidance / FY 2026E
Collaboration revenue ($M)	40.1	6.2	5.5	1.3	~5
R&D expense ($M)	-235	-178	-141	~-26	~-100 to -110
G&A expense ($M)	-58	-43	-36	~-8	~-32
Total OpEx ($M)	-293	-221	-177	-34.3	~-135 (post Aug 25 restruct)
Net loss ($M)	-260	-191	-160	-31.2	~-125
Cash EOP ($M)	342	280	208	174.8	~70 (end FY26)
Shares OS (M)	99.5	106.0	113.0	115.35	~118 (organic dil.)

Note: FY23 revenue distorted by Janssen termination $40M payment. Post-Janssen pivot reduced OpEx from $293M to $177M (-40%). Aug 2025 restructuring shaved another ~20%. Cash burn run-rate $130-140M/yr from FY26.

Quarterly dynamics — last 5 quarters
Metric	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26
Revenue ($M)	1.5	1.4	1.4	1.2	1.3
R&D ($M)	-36	-37	-34	-34	-26
OpEx ($M)	-43	-44	-42	-43	-34.3
Net loss ($M)	-39	-41	-41	-39	-31.2
Cash EOP ($M)	272.7	250	226	208	174.8

Financial position and sustainability

Cash runway (months to depletion)

~24 mos

Net cash as % of market cap

79%

OpEx reduction (FY23 → FY25 → FY26E)

-54%

YoY dilution (FY24 → FY25 → Q1 26)

+8.77%

account_tree

Business model — iPSC-derived off-the-shelf CAR T & NK cell therapy platform

Pure clinical-stage cell therapy biotech: iPSC platform pivot from oncology to autoimmune

Fate Therapeutics develops off-the-shelf engineered cell therapies derived from induced pluripotent stem cells (iPSCs). The platform enables scalable manufacturing of CAR T and CAR NK cell products — a differentiated approach vs autologous (patient-derived) CAR T. After the January 2023 termination of the Janssen collaboration (which had implied up to $3B in milestones), management pivoted strategy toward autoimmune indications, where conditioning-free off-the-shelf CAR T offers compelling clinical and commercial logic. Lead asset FT819 (CD19 CAR T) is in Phase 1 SLE (n=21) and entering Phase 2 RECLAIM-LN (lupus nephritis, ~53 patients, single 900M cell dose, CRR primary endpoint, H2 2026 initiation). Multiple earlier programs in CAR NK + solid tumors. Aug 2025 corporate restructuring extended runway into 2028. The path to value: clinical execution on FT819 → potential partnership / re-engagement with strategic biopharma.

FT819 — CD19 CAR T (autoimmune) ~$1.5B peak unrisked (LN) 🟢 Phase 1/2 advancing Lead asset. Phase 1 SLE n=21, clean safety (no Grade >2 CRS, no DLT). RECLAIM-LN (Phase 2 registrational) H2 2026 initiation. FDA CDRP designation. Conditioning-free or bendamustine-light approach differentiates vs autologous CAR T. FT522 / FT825 / FT836 — early oncology + autoimmune ~$0.5B combined peak unrisked 🟡 Phase 1 / preclinical FT522 (CAR NK, B-cell lymphoma + autoimmunity). FT825 (CAR T solid tumors). FT836 (MICA/B CAR T solid tumors, early safety). Optionality but low probability-weighted value vs FT819. FT839 — next-gen autoimmune basket IND-stage 🟡 IND nearing submission FT839 nearing IND submission for Phase 1 autoimmune basket trial. Represents next-generation iPSC engineering. Together with FT836, validates iPSC platform extensibility but adds little NTM value.

gavel

Legal, regulatory and risk analysis

FT819 Phase 2 binary clinical risk

High

RECLAIM-LN Phase 2 (potentially registrational) starts H2 2026. CRR (complete renal response) at 6 months is the primary endpoint. Single-arm n=53 design — bar is high. Negative or ambiguous data would collapse the equity story; positive would re-rate toward consensus $5.27.

Autoimmune CAR T competitive intensity

High

Cabaletta (CABA-201 autologous), Kyverna (KYV-101), Allogene (ALLO-329), Caribou (CB-010 autoimmune extension), Bristol/Galapagos partnership. Even successful FT819 data would land in a crowded competitive landscape; differentiation = off-the-shelf manufacturing economics.

Dilution overhang

High

Cash runway into 2028 = ~24 months. Equity raise highly likely within 12-15 months at depressed price ($2-3 range). Modeled −$0.85/sh dilution haircut in FV. Capital raise execution itself is binary: tighter terms in down market = larger dilution.

2023 securities class action pending

Moderate

Securities class action filed June 2023 (Janssen termination), Wolchko/Dulac/Valamehr named. Class period Apr 2020 - Jan 2023. No resolution disclosed as of June 2026 — settlement/judgment overhang remains. Reserve liability not quantified in public disclosures.

Cell therapy manufacturing complexity

Moderate

iPSC manufacturing platform is differentiated but complex; quality, batch consistency, and scale-up remain ongoing challenges across the industry. CMC readiness for Phase 2/3 will be carefully scrutinized — FDA CDRP designation helps, doesn't eliminate.

Net cash floor protects downside

Positive

$174.8M cash, zero debt = $1.52/sh net cash, 79% of current market cap. Provides hard floor in any going-concern scenario. Stock trades near cash floor before pipeline value — asymmetric R/R setup.

iPSC platform IP + first-mover

Positive

FATE pioneered iPSC-derived off-the-shelf cell therapy. Multi-year head start on manufacturing know-how and IP estate. Platform value as potential strategic asset for tier-1 biopharma seeking off-the-shelf CAR T optionality.

FDA CDRP designation + clean Phase 1 safety

Positive

FDA selected FT819 into the CMC Development and Readiness Pilot program — accelerated FDA dialogue. Phase 1 SLE n=21 shows no Grade >2 CRS, no DLT — safety profile differentiated vs more toxic autologous CAR T regimens. Regulatory pathway de-risked at the margin.

article

SWOT analysis

Strengths

+$174.8M cash, zero debt, runway into 2028 = ~79% of market cap as cash floor
+iPSC platform pioneer: off-the-shelf manufacturing economics vs autologous
+FT819 Phase 1 SLE n=21 safety profile clean (no Grade >2 CRS, no DLT)
+FDA CDRP designation accelerates regulatory dialogue
+Multi-asset pipeline (FT819, FT522, FT825, FT836, FT839) provides optionality

Weaknesses

−No commercial revenue; collab revenue only $5M annual run-rate
−$130-140M/yr cash burn → equity raise required within 12-15 months
−Post-Janssen 2023 termination overhang: market remains skeptical of partnership claims
−2023 securities class action unresolved; reserve liability not quantified
−FT819 must beat established autologous CAR T efficacy bar in autoimmune

Opportunities

→RECLAIM-LN positive readout could trigger 2-3x re-rating toward consensus $5.27
→Big pharma autoimmune CAR T M&A interest (BMS-Cellectis, AbbVie-Capstan precedents)
→FT522 CAR NK in autoimmunity extends platform addressable market
→Capital raise at higher price post-positive data limits dilution
→EV/Cash 0.27x vs peer median 0.65x leaves room for mean-reversion

Threats

!RECLAIM-LN initiation slip → cash burned without milestone validation
!Negative or ambiguous FT819 efficacy data → 50%+ downside
!Forced dilutive raise in weak biotech tape → 30-40% dilution risk
!Cabaletta / Allogene / Kyverna / Caribou competitive intensification
!2023 class action settlement could consume meaningful cash if judgment unfavorable

article

Summary by assessment area

🟡 Financial risk — Moderate

$174.8M cash, zero debt, ~24 months runway
Net cash 79% of market cap — hard floor
Dilution within 12-15 months is base case

🔴 Clinical risk — High

RECLAIM-LN Phase 2 is binary; single-arm CRR endpoint
Autoimmune CAR T competitive landscape intense
Multi-program pipeline mitigates single-asset exposure

🔵 Valuation risk — Favorable asymmetry

EV/Cash 0.27x vs peer median 0.65x — deep discount
Base FV $2.80 → +44% upside; Bull $4.50-6.00 = +132-209%
Consensus $5.27 reflects analyst optimism on FT819 PoA

2026-09-30 product

RECLAIM-LN Phase 2 potentially registrational trial — dosing initiation

short-term Impact: High Direction: Binary

Phase 2 in refractory lupus nephritis, ~53 patients, 900M cells single dose post-bendamustine conditioning, CRR at 6 months primary endpoint. Initiation confirms timeline and de-risks 2027-2028 readout. Slip would compress equity story.

2026-08-12 earnings

Q2 2026 Earnings Release (estimated)

short-term Impact: Medium Direction: Neutral

Cash burn rate, runway update, RECLAIM-LN timeline confirmation. Less binary than clinical events but key for tracking financing window. Expected cash ~$140M end Q2.

2026-11-08 product

FT819 Phase 1 SLE — Updated Data at ACR 2026

medium-term Impact: High Direction: Binary

Updated Phase 1 data at American College of Rheumatology Congress, November 2026. Larger patient cohort (likely n=30+), longer follow-up. Efficacy signal (SRI-4, BICLA, lupus low disease activity) critical for RECLAIM-LN read-through.

2027-03-31 capital_markets

Expected equity raise window (12-15 months from now)

medium-term Impact: High Direction: Bearish

With runway into 2028 and $130-140M/yr burn, equity raise is near-certainty within 12-15 months. Timing/price highly contingent on RECLAIM-LN data. Pre-data raise = larger dilution at depressed price; post-positive-data raise = smaller dilution at higher price.

2026-09-30 regulatory

FT839 IND Submission — Autoimmune basket trial

short-term Impact: Medium Direction: Bullish

Next-generation FT839 IND filing for Phase 1 autoimmune basket trial. Validates platform extensibility beyond FT819. Modest market-mover but supports iPSC platform narrative.

2026-12-31 regulatory

2023 securities class action — settlement / motion outcome

medium-term Impact: Medium Direction: Binary

Class action filed June 2023 over Janssen termination disclosures. Procedural milestones (motion to dismiss, summary judgment, settlement discussions) expected in late 2026. Adverse outcome could consume material cash; favorable removes overhang.

2027-02-25 earnings

Q4 2026 / FY26 Results + RECLAIM-LN Enrollment Update

long-term Impact: High Direction: Binary

FY26 wrap with RECLAIM-LN enrollment pace (likely 10-20 patients dosed by then), cash position, and FY27 guidance. Enrollment momentum signal for 2027/2028 timeline. Cash runway clarity influences raise timing.

2027-06-30 ma

Potential strategic partnership / acquisition

long-term Impact: High Direction: Bullish

iPSC platform with FT819 LN/SLE Phase 2 readout = logical bolt-on for large pharma seeking autoimmune CAR T off-the-shelf optionality (BMS, Pfizer, AbbVie, AstraZeneca). Precedents: BMS-Cellectis, AbbVie-Capstan. Bull tail outcome.

{ "verdict_label": {"it": "Moderatamente Attraente", "en": "Moderately Attractive"}, "verdict_text": {"it": "Biotech clinico post-pivot Janssen con $174.8M cassa (~79% market cap), runway al 2028, catalizzatore binario H2 2026 (RECLAIM-LN fase 2 in nefrite lupica). Dati Fase 1 SLE puliti sulla sicurezza. Cassa $1.52/sh limita il downside vs $1.94; consensus $5.27 mostra reward asimmetrico se esecuzione tiene. Diluzione attesa e settore autoimmune CAR T affollato limitano il base case.", "en": "Post-Janssen-pivot clinical biotech with $174.8M cash (~79% mkt cap), runway into 2028, binary catalyst H2 2026 (RECLAIM-LN Phase 2 in lupus nephritis). FT819 Phase 1 SLE data clean on safety. Cash floor $1.52/sh limits downside vs $1.94; consensus $5.27 shows asymmetric reward if execution holds. Expected dilution and crowded autoimmune CAR T cap the base case."}, "bull_points": [ {"it": "Cassa $174.8M = 79% market cap: pavimento netto $1.52/sh sul prezzo", "en": "Cash $174.8M = 79% mkt cap: $1.52/sh hard floor on price"}, {"it": "FT819 RECLAIM-LN Phase 2 inizia H2 2026, FDA CDRP designation", "en": "FT819 RECLAIM-LN Phase 2 starts H2 2026, FDA CDRP designation"}, {"it": "EV/Cash 0.27x vs peer median 0.65x: spazio di mean-reversion", "en": "EV/Cash 0.27x vs peer median 0.65x: mean-reversion room"} ], "bear_points": [ {"it": "Burn $130-140M/anno, runway solo 2 anni, raise diluitivo entro 12-15 mesi", "en": "$130-140M/yr burn, only 2 yrs runway, dilutive raise within 12-15 months"}, {"it": "Spazio autoimmune CAR T affollato: Cabaletta, Allogene, Kyverna, Caribou", "en": "Autoimmune CAR T crowded: Cabaletta, Allogene, Kyverna, Caribou"}, {"it": "Class action 2023 ancora pendente: overhang non quantificato", "en": "2023 class action still pending: unquantified overhang"} ], "risks": [ {"it": "Slittamento o esito ambiguo RECLAIM-LN: crollo della narrativa equity", "en": "RECLAIM-LN slip or ambiguous outcome: equity narrative collapse"}, {"it": "Raise forzata in mercato biotech debole: -30% dilution", "en": "Forced raise in weak biotech tape: -30% dilution"}, {"it": "Concorrenza biopharma maggiore in autoimmune CAR T offerta", "en": "Larger biopharma competition in autoimmune CAR T offerings"} ] }

Sources & Disclaimer

Sources: Fate Therapeutics 8-K Q1 2026 (May 13, 2026 release), Form 10-Q Q1 2026, Globe Newswire / ACR/EULAR / European Congress of Rheumatology press releases, Yahoo Finance, Stock Analysis, MarketBeat, Stocktitan, BioSpace, TipRanks, Public.com, Simply Wall St, ChartMill, MarketScreener, Pitchbook, Investor Lawyers (2023 class action). Market data — last verified close 2026-06-09: FATE $1.94, market cap ~$222M, 52W: $0.91–$2.88, shares outstanding 115.35M. Short interest: 9.92% (11.44M shares). Cash $174.8M / zero debt / net cash $174.8M / $1.52 per share. Q1 2026 collab revenue $1.3M, OpEx $34.3M (-20% YoY), net loss $31.2M (-$0.26/sh). Cash runway into 2028. FT819 Phase 1 SLE n=21 (as of May 14, 2026 cutoff): no Grade >2 CRS, no DLT. RECLAIM-LN Phase 2 lupus nephritis trial (~53 pts, 900M cells, CRR primary endpoint) to initiate H2 2026. FDA CDRP designation for FT819. Analyst consensus: average target $5.27, median $5.00 (12-18 analysts, post Q1 2026 updates; mostly Buy ratings). 2023 securities class action (Janssen termination disclosures) still pending. This document is for informational purposes only and does not constitute financial or investment advice.